Gecacitinib Hydrochloride Tablets

DRUG4 trials

Sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Yujun DONG

Conditions

Chronic Graft Versus Host DiseaseHealthyLymphomaNon-small Cell Lung Cancer

Phase 1

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

RecruitingNCT06883526

Suzhou Zelgen Biopharmaceuticals Co.,LtdLymphoma

Start: 2025-05-16End: 2027-05-31Target: 60Updated: 2026-01-05

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

RecruitingNCT06903377

Suzhou Zelgen Biopharmaceuticals Co.,LtdNon-small Cell Lung Cancer

Start: 2025-05-23End: 2027-05-31Target: 50Updated: 2026-01-05

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

RecruitingNCT07012304

Yujun DONGChronic Graft Versus Host Disease

Start: 2025-06-30End: 2029-02-28Target: 24Updated: 2025-06-10

A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.

Active, not recruitingNCT07565597

Suzhou Zelgen Biopharmaceuticals Co.,LtdHealthy

Start: 2026-05-12End: 2027-03-01Updated: 2026-06-08